Sign In
Buy BEAM
$29.55
+0.590 (+2.04%)
At Close: Jun 03, 2026
Beam Therapeutics: Great Potential, But Patience Is Needed
09:40am, Friday, 27'th Feb 2026
Beam Therapeutics Inc. is rated a Buy for its leadership in proprietary base-editing gene therapy, targeting significant unmet needs in hematology and liver diseases. BEAM's risto-cel shows superior e
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y
12:06pm, Wednesday, 25'th Feb 2026
Beam Therapeutics posts a narrower Q4 loss as revenues surge past estimates. It secures $500M financing, extending its cash runway into mid-2029.
Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript
04:57pm, Tuesday, 24'th Feb 2026
Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript
What's Going On With Beam Therapeutics Stock?
02:07pm, Tuesday, 24'th Feb 2026
Beam announced a loss per share of 10 cents, far surpassing the consensus estimate of a loss of 99 cents. Additionally, the company reported revenue of $114.11 million, dramatically exceeding expectat
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Beats Revenue Estimates
09:51am, Tuesday, 24'th Feb 2026
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a loss of $1.09 per share a year ago.
New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
07:00am, Tuesday, 24'th Feb 2026
$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Antici
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the
Cathie Wood Buys COIN After 16% Jump
05:42am, Monday, 16'th Feb 2026
Cathie Wood is once again leaning into momentum. ARK Invest added to several high-profile names on Feb. 13, buying into stocks that had just rallied on earnings
Beam Therapeutics Senior Vice President Sells 6,198 Shares for $216,933
03:46am, Sunday, 01'st Feb 2026
Bethany J. Cavanagh sold 6,198 direct shares for a transaction value of approximately $216,933 at a weighted average price of around $35.00 per share. The sale represented 15.11% of direct post-transa
Christine Bellon Sells 1,371 Shares of Beam Therapeutics (NASDAQ:BEAM) Stock
05:35am, Wednesday, 28'th Jan 2026
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) insider Christine Bellon sold 1,371 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $3
Beam Therapeutics (NASDAQ:BEAM) Insider Christine Bellon Sells 18,629 Shares of Stock
04:39am, Wednesday, 21'st Jan 2026
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) insider Christine Bellon sold 18,629 shares of Beam Therapeutics stock in a transaction dated Thursday, January 15th. The stock was sold at an a
SG Americas Securities LLC Purchases 36,004 Shares of Beam Therapeutics Inc. $BEAM
05:24am, Monday, 19'th Jan 2026
SG Americas Securities LLC grew its position in Beam Therapeutics Inc. (NASDAQ: BEAM) by 498.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional invest
Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
03:35am, Wednesday, 14'th Jan 2026
Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Beam Therapeutics: Pivoting From Platform To Execution Stage
02:54pm, Tuesday, 13'th Jan 2026
Beam Therapeutics Inc. pivots from platform story to execution-driven thesis, with regulatory clarity accelerating BEAM-302 and Risto-cel in 2026. BEAM-302's "in vivo" gene editing for AATD achieved a
